Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 9.74 Million USD | -79.87% |
| 2022 | 48.39 Million USD | 7.42% |
| 2021 | 45.05 Million USD | 66.02% |
| 2020 | 27.13 Million USD | 85.6% |
| 2019 | 14.62 Million USD | 349.35% |
| 2018 | 3.25 Million USD | 201.86% |
| 2017 | 1.07 Million USD | -65.94% |
| 2016 | 3.16 Million USD | 37.14% |
| 2015 | 2.3 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 337 Thousand USD | -72.98% |
| 2006 | 1.24 Million USD | 725.83% |
| 2005 | 151 Thousand USD | -60.47% |
| 2004 | 382 Thousand USD | 57.85% |
| 2003 | 242 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 8.39 Million USD | 0.0% |
| 2024 Q1 | 9.07 Million USD | 0.0% |
| 2023 Q3 | 10.39 Million USD | -5.74% |
| 2023 Q4 | 9.74 Million USD | -6.29% |
| 2023 FY | 9.74 Million USD | -79.87% |
| 2023 Q2 | 11.02 Million USD | -77.04% |
| 2023 Q1 | 48.03 Million USD | -0.75% |
| 2022 Q1 | 44.74 Million USD | -0.69% |
| 2022 Q4 | 48.39 Million USD | 0.08% |
| 2022 Q2 | 44.11 Million USD | -1.4% |
| 2022 FY | 48.39 Million USD | 7.42% |
| 2022 Q3 | 48.36 Million USD | 9.62% |
| 2021 Q1 | 26.61 Million USD | -1.92% |
| 2021 FY | 45.05 Million USD | 66.02% |
| 2021 Q3 | 45.53 Million USD | -0.94% |
| 2021 Q4 | 45.05 Million USD | -1.05% |
| 2021 Q2 | 45.96 Million USD | 72.69% |
| 2020 Q3 | 27.65 Million USD | 8.47% |
| 2020 Q4 | 27.13 Million USD | -1.85% |
| 2020 FY | 27.13 Million USD | 85.6% |
| 2020 Q2 | 25.49 Million USD | 80.54% |
| 2020 Q1 | 14.12 Million USD | -3.43% |
| 2019 Q2 | 13.78 Million USD | -1.06% |
| 2019 Q1 | 13.92 Million USD | 328.06% |
| 2019 Q3 | 13.57 Million USD | -1.51% |
| 2019 FY | 14.62 Million USD | 349.35% |
| 2019 Q4 | 14.62 Million USD | 7.72% |
| 2018 Q2 | 3.06 Million USD | 2.13% |
| 2018 Q4 | 3.25 Million USD | 3.14% |
| 2018 FY | 3.25 Million USD | 201.86% |
| 2018 Q1 | 2.99 Million USD | 178.2% |
| 2018 Q3 | 3.15 Million USD | 3.0% |
| 2017 Q4 | 1.07 Million USD | -39.91% |
| 2017 FY | 1.07 Million USD | -65.94% |
| 2017 Q3 | 1.79 Million USD | -24.3% |
| 2017 Q2 | 2.36 Million USD | -3.51% |
| 2017 Q1 | 2.45 Million USD | -22.4% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | 3.16 Million USD | 0.0% |
| 2016 FY | 3.16 Million USD | 37.14% |
| 2016 Q3 | - USD | 0.0% |
| 2015 FY | 2.3 Million USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | 99 Thousand USD | -70.62% |
| 2008 FY | - USD | -100.0% |
| 2007 Q2 | 800 Thousand USD | -21.95% |
| 2007 FY | 337 Thousand USD | -72.98% |
| 2007 Q1 | 1.02 Million USD | -17.8% |
| 2007 Q3 | 571 Thousand USD | -28.63% |
| 2007 Q4 | 337 Thousand USD | -40.98% |
| 2006 Q4 | 1.24 Million USD | -16.7% |
| 2006 Q2 | 1.74 Million USD | 1499.08% |
| 2006 FY | 1.24 Million USD | 725.83% |
| 2006 Q3 | 1.49 Million USD | -14.11% |
| 2006 Q1 | 109 Thousand USD | -27.81% |
| 2005 Q4 | 151 Thousand USD | -21.76% |
| 2005 Q1 | 296 Thousand USD | -22.51% |
| 2005 Q3 | 193 Thousand USD | -17.52% |
| 2005 Q2 | 234 Thousand USD | -20.95% |
| 2005 FY | 151 Thousand USD | -60.47% |
| 2004 FY | 382 Thousand USD | 57.85% |
| 2004 Q3 | 185 Thousand USD | 0.0% |
| 2004 Q4 | 382 Thousand USD | 106.49% |
| 2003 FY | 242 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -767.391% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -654.025% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 77.725% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -97320.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 5.856% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -7063.235% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -7997.953% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -12.08% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 80.069% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -160.221% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 65.701% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 93.55% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -4348.422% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -968.788% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -420.485% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 48.906% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -132.284% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 90.663% |
| Statera Biopharma, Inc. | 11.43 Million USD | 14.777% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -1230.874% |
| Trevena, Inc. | 35.23 Million USD | 72.35% |
| Vaxxinity, Inc. | 13.26 Million USD | 26.542% |
| Vaccinex, Inc. | 26 Thousand USD | -37369.231% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |